Möchten Sie immer auf dem neuesten Stand bleiben?

This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn. Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results...

BioNTech gab heute positive Ergebnisse aus der primären Analyse einer Phase-2-Kohorte mit Trastuzumab Pamirtecan bei HER2+ Gebärmutterkrebs bekannt.

BioNTech today announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in HER2+ endometrial cancer.

STAFFORD, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...

This press release is not intended for UK media HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1...

- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – -...

Achieved ~60% reduction in operating costs through a focused cost optimization plan DiversImmune® platform positioned to unlock additional pipeline value Reverse stock split supports Nasdaq...

This press release is not intended for UK and US media.  HERNEXEOS® (zongertinib tablets) has been approved based on an objective response rate of 71% (N=75), as demonstrated in the Beamion-LUNG 1...

This press release is not intended for UK media.  HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 75% (N=71), as demonstrated in the Beamion-LUNG 1 clinical...

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager